Evidence map›Paper›PMID 37021537›Full record

ArticleHaematologica2023

Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network.

Christina M Termini, Anna Moseley, Megan Othus, Frederick R Appelbaum, Thomas R Chauncey, Harry P Erba, Min Fang, Stanley C Lee, Jasmine Naru, Era L Pogosova-Agadjanyan and 5 more

Abstract readLetter
In one paragraph

Article in Haematologica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Christina M TerminiTranslational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA. ctermini@fredhutch.org.
Anna MoseleySWOG Statistical Center, Fred Hutch Cancer Center, Seattle, WA, USA.
Megan OthusSWOG Statistical Center, Fred Hutch Cancer Center, Seattle, WA, USA.
Frederick R AppelbaumDepartments of Oncology and Hematology, University of Washington, Seattle, WA, USA; Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA.
Thomas R ChaunceyDepartments of Oncology and Hematology, University of Washington, Seattle, WA, USA; VA Puget Sound Health Care System, Seattle, WA, USA.
Harry P ErbaDuke Cancer Institute, Durham, NC, USA.
Min FangTranslational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Stanley C LeeTranslational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA, USA; Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Jasmine NaruTranslational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA, USA.
Era L Pogosova-AgadjanyanTranslational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA, USA.
Jerald P RadichTranslational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA, USA; Departments of Oncology and Hematology, University of Washington, Seattle, WA, USA.
Cheryl L WillmanDepartment of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.
Feinan WuGenomics and Bioinformatics Shared Resource, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Soheil MeshinchiTranslational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA.
Derek L StirewaltTranslational Science and Therapeutics Division, Fred Hutch Cancer Center, Seattle, WA, USA; Departments of Oncology and Hematology, University of Washington, Seattle, WA, USA.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2M
SWOG U24 Funding for 2026-2027U24CA196175 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI James Michael Rae, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$37.6M
Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg GenotypeR01CA190661 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STIREWALT, DEREK L · 2016 to 2020
$2.7M
Discovery and Optimization of AML Prognostic BiomarkersR01CA160872 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STIREWALT, DEREK L · 2012 to 2016
$2.5M
NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA160872NCI NIH HHS R01 CA190661NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180888NCI NIH HHS U24 CA196175
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myeloid, AcuteHumansPrognosisRisk AssessmentTreatment Outcome

Identifiers

PMID37021537
PMCPMC10620555

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.